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Abstract
G-protein coupled receptors (GPCRs) are among the most diverse
and ubiquitous proteins in all of biology. The epidermal growth factor-
seven span transmembrane (EGF-TM7) subfamily of adhesion GPCRs
is a small subset whose members are mainly expressed on the surface
of leukocytes. The EGF domains on the N-terminus add significant size
to these receptors and they are considered to be among the largest
members of the TM7 family. Although not all of their ligands or down-
stream targets have been identified, there is evidence implicating the
EGF-TM7 family diverse processes such as cell adhesion, migration,
inflammation, and autoimmune disease. Recent studies have identi-
fied expression of EGF-TM7 family members on human neoplasms
including those of the thyroid, stomach, colon, and brain. Their pres-
ence on these tissues is not surprising given the ubiquity of GPCRs,
but because their functional significance and pathways are not com-
pletely understood, they are of tremendous clinical and scientific inter-
est. Current evidence suggests that expression of certain EGF-TM7
receptors is correlated with tumor grade, confers a more invasive phe-
notype, and increases the likelihood of metastatic disease. In this
review, we will discuss the structure, function, and regulation of these
receptors. We also describe the expression of these receptors in
human cancers and explore their potential mechanistic significance. 
The adhesion G-protein coupled receptor and epidermal growth factor seven-span transmembrane subfamily
The seven-span transmembrane (7TM or TM7) receptors are
involved in a variety of signaling pathways for hormones, neurotrans-
mitters, chemokines, ions, and sensory receptors for light, smell, and
taste. They represent the largest known gene family in animals and are
the target, either directly or indirectly, of most pharmaceuticals sold
worldwide.1,2 The epidermal growth factor (EGF) family is the fifth
most common protein family, with EGF domains present in 3% of all
potential proteins.3
The TM7 family can be classified by a variety of schemes, including
division into three classes based on amino acid sequence. Class A, the
rhodopsin superfamily, includes rhodopsin and other light receptors,
epinephrine and adrenergic receptors, and olfactory receptors. Class B,
the secretin receptor superfamily, is considerably smaller and contains
receptors for gastrointestinal and other peptide hormones including
growth hormone-releasing hormone, corticotropin-releasing hormone,
calcitonin, and parathyroid hormone. Class C, the metabotropic gluta-
mate receptor superfamily, features the gamma-aminobutyric acid
(GABA) receptor as well as calcium-sensing and taste receptors. The
class B TM7 receptors can be further divided into three subgroups: i)
B1, which contains peptide hormone receptors; ii) B2, featuring TM7
receptors with a long N-terminal extracellular region (LNB-TM7); iii)
B3, comprised of methuselah-like proteins.4 The LNB-TM7 family has
over 30 members with large extracellular regions including the EGF-
like domains.5 There are six members of the EGF-TM7 subfamily: i)
CD97; ii) EGF-like module containing mucin-like hormone receptor 1
(EMR1); iii) EMR2; iv) EMR3; v) EMR4; and vi) EGF-TM7-latrophilin-
related protein (ETL).6-11 CD97, EMR2, and EMR3 are found on chro-
mosome 19 at loci 19p13.1, while EMR1 and EMR4 are on 19p13.3.
CD97 and EMR1 are closely linked to RFX1 and RFX2, a set of transcrip-
tion factors involved in immune system function, suggesting that both
families arose through multiple duplication events and eventually
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diverged.12,13 Phylogenetic analysis prompted the development of the
GRAFS classification system for G-protein coupled receptors, which
consists of five families: i) glutamate (G); ii) rhodopsin (R); iii) adhe-
sion (A); iv) frizzled/taste2 (F); and v) secretin (S).14 The glutamate
receptor family possesses a unique Venus fly trap N-terminus domain
that allows the receptor to close around its ligand. Members of this fam-
ily include the metabotropic glutamate receptors, GABA receptors, sev-
eral putative taste receptors (TAS1), and a single calcium-sensing
receptor. The rhodopsin family is the largest amongst G protein coupled
receptors (GPCRs) and contains receptors for neuropeptides,
chemokines, prostaglandins, biogenic amines, glycoprotein hormones,
and olfactory and visual receptors.
The EGF-TM7 receptors belong to the adhesion receptor family. The
adhesion GPCRs are divided into eight clusters or groups identified by
Roman numerals.15 All EGF-TM7 receptors are members of Group II
except for ETL, which is found in Group I. Under the GRAFS classifica-
tion system, all adhesion GPCRs feature GPCR-like transmembrane
domains with an N-terminus containing an adhesion-like motif such as
EGF-like repeats, mucin-like regions, or cysteine-rich motifs, and are
believed to play a role in cell adhesion.4,14,16 EMR2 and EMR3 are the
only members of the adhesion GPCR family without mouse ortho-
logues, further supporting the hypothesis that the EGF-TM7 subfamily
arose from duplication events. 
The fourth family of GPCRs contains two clusters and is referred to
as the frizzled/taste2 receptor family. This group of taste receptors
(TAS2) contains consensus sequences unique to the frizzled receptors
and absent in the TAS1 receptors of the glutamate receptor family.14
Frizzled receptors are notable for mediating Wnt signaling and regulate
cell fate and polarity during development.14,17,18 Members of the
secretin receptor family are capable of binding large, typically
paracrine-acting peptides. They are named after the first discovered
member of the family and include the secretin receptor, glucagon
receptor, calcitonin receptor, corticotropin-releasing hormone receptor,
growth hormone-releasing hormone receptor, and others.14 Despite the
tremendous diversity in the TM7 family, the EGF-TM7 subfamily
remains unique for several reasons. First, not much is known of their
downstream targets and specific ligand interactions. Furthermore, due
to their fairly restricted expression profile, the functional significance
of these receptors remains elusive. Finally, and perhaps most interest-
ingly, members of this family have been detected in various malignan-
cies, implicating them in tumor invasion, metastatic spread, and angio-
genesis. 
Receptor structure
Traditional GPCRs operate through a well-understood molecular cas-
cade. Ligand binding stabilizes the receptor and stimulates a het-
erotrimeric guanine nucleotide-binding regulatory (G) protein to dis-
sociate into  and  subunits. These subunits modulate a number of
effectors including adenylyl cyclase, phospholipase, phosphodiesterase,
and ion channels, which subsequently regulate the concentration of
second-messengers that elicit a cellular response. It is important to note
that there is evidence suggesting certain TM7 receptors may operate
through G-protein-independent mechanisms. For example, in
Dictyostelium, a unicellular eukaryote, cyclic adenosine monophos-
phate receptors (cAMP) are capable of inducing calcium influx, mito-
gen-activated protein kinase 1 activation, and cAMP receptor 1 phos-
phorylation by G-protein-independent mechanisms.19 Other TM7 recep-
tors, such as those of the EGF-TM7 subfamily, may facilitate cell adhe-
sion without activation of their signaling cascades, although this is less
likely given the tendency of structurally similar proteins to engage the
G  subunit. The EGF-TM7 receptors contain distinct regions including a
cleavable signal peptide, N-terminal EGF domain region, stalk, class B
TM7 region, and cytoplasmic tail (Figure 1). Most are expressed as het-
erodimers consisting of extracellular and TM7/cytoplasmic domains.
The extracellular domains of these receptors represent some of the
largest in the entire TM7 family and typically contain adjacent EGF-like
domains. Like the TM7 family, the EGF domain is among the most ubiq-
uitous in biology. EGF domains are linked to numerous physiologic
processes including cell adhesion, neural development, coagulation,
and fibrinolysis.20 Mutations in the EGF domains of biologically impor-
tant receptors are associated with diverse human diseases. For exam-
ple, mutations of the low-density lipoprotein receptor, factor IX, and fib-
rillin cause familial hypercholesterolemia, hemophilia B, and Marfan
syndrome, respectively.21-23
The EGF-TM7 family is almost universally characterized by the pres-
ence of alternative splicing, producing isoforms with variable number
and arrangement of EGF domains.24 Within this family, the EGF
domains of EMR2 and CD97 demonstrate the most homology, differing
by only six amino acids.8 Although EGF domains mediate the interac-
tions between these receptors and their ligands in a calcium-depend-
ent fashion, the intricacies of ligand binding are not fully understood.
Calcium is believed to provide conformational stability to inter-domain
linkages, producing EGF repeats that are highly resistant to proteoly-
sis.25 Such properties seem ideally suited for cell-cell or cell-extracellu-
lar matrix interactions, particularly those involved in adhesion or
migration. Additionally, these receptors may interact with other cell
surface proteins as recent data has demonstrated heterodimerization
of CD97 with lysophosphatidic acid receptor 1 (LPAR1) in prostate can-
cer cells.26
Expression of epidermal growth factor epidermal growth factor seven-span transmembrane members
EMR2 is expressed on monocytes, macrophages, myeloid dendritic
cells, and granulocytes, but not lymphocytes.8,27 There are five EMR2
isoforms, four of which are depicted in Figure 1, that differ in their
number of EGF-like domains. Interestingly, EMR2 and EMR3 are the
[Oncology Reviews 2014; 8:242] [page 21]
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Figure 1. Isoforms of the epidermal growth factor (EGF)-like
module containing mucin-like hormone receptor 2 (EMR2).
These receptors feature seven-span transmembrane domains
(shown in red), a mucin stalk (green), and varying numbers of
EGF domains (blue triangles). The EGF-domains can be fairly
large, making these proteins among the largest G-protein coupled
receptors.
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only members of the EGF-TM7 family that lack mouse orthologs. EMR2
expression is highest in mature CD16+ monocytes, macrophages, and
blood dendritic cell antigen-3+ myeloid dendritic cells, and lowest in
granulocytes.27
Functional significance of the epidermalgrowth factor-like module containing mucin-like hormone receptor 2 family in leukocytes
The study of EMR2 is hampered by the lack of mouse orthologues. As
the EGF domains of EMR2 demonstrate significant homology, it is not
surprising that chondroitin sulfate (CS) has been identified as a lig-
and.28 CS is one of two major types of glycosaminoglycans (GAGs), the
other being heparin/heparin sulfate, which differ by the composition of
their amino sugars. Furthermore, there are three types of CS: i) chon-
droitin sulfate A (CSA); ii) chondroitin sulfate B (CSB), which includes
dermatan sulfate, an isomer with variable glucuronic acid residues; iii)
chondroitin sulfate C (CSC).29 EMR2 has been shown to bind dermatan
sulfate on B cells, but does not induce signaling or cell activation.30
This supports previous findings suggesting a role for EGF-TM7 family
receptors in cell adhesion.
Functionally, EMR2 has also been implicated in autoimmune disease
and neutrophil function. EMR2-positive macrophages and dendritic
cells are increased in the synovium of patients with rheumatoid arthri-
tis (RA).29 GAG expression in the inflammatory synovium and chondro-
cytes in RA is predominantly dermatan sulfate, while fibrotic synovium
is generally comprised of CSA and CSC.31 Thus, the interaction of
EMR2 with dermatan sulfate provides a plausible mechanism underly-
ing the persistent inflammation in RA and other autoimmune diseases.
Additionally, EMR2 has been implicated in neutrophil function by medi-
ating activation and cytokine secretion in the presence of lipopolysac-
charide and IL-10.32 Circulating neutrophils in patients with systemic
inflammation also exhibit elevated EMR2 expression.33 Additionally,
foamy macrophages in atherosclerotic vessels and splenocytes in
patients with Gaucher’s disease have been shown to express EMR2.34
Expression of epidermal growth factor-likemodule containing mucin-like hormone receptor 2 in cancers
Although once thought to be leukocyte-restricted, several studies
have identified EMR2 in human neoplasms. EMR2 expression has been
characterized in colorectal, breast, and brain cancers, although hetero-
geneity in expression patterns is detected even within these tumor
types. Aust et al. found that among 81 colorectal cancer cell lines, only
8 demonstrated greater than 50% expression of the EMR2 protein,
though strong EMR2 expression was observed in a subpopulation of
tumor-infiltrating macrophages.35 Similarly, Davies et al. examined 5
breast cancer cell lines and found that only 2 qualified as high
expressers, with EMR2 localization restricted to the peripheral mem-
brane and perinuclear cytoplasm.36 Recently, our group examined
EMR2 expression in primary glioblastoma (GBM) tissue derived from 5
patients as well as 3 established GBM cell lines, showing heteroge-
neous expression of EMR2 across all specimens.37 Furthermore, a
cDNA microarray analysis of early-stage and advanced bladder tumors
found EMR2 to be among the top-ranked genes identified.38 Unlike
CD97, the most well-characterized member of the EGF-TM7 family,
EMR2 is not expressed in gastric, pancreatic, and esophageal carcino-
mas, which may be explained by the multiplicity of EMR2 mRNA iso-
forms present in single cell lines or types.39 As such, while EMR2
immunopositivity can be encountered in these neoplasms, not all
tumors of any given ontology will express this protein.
Functional significance of epidermal growthfactor-like module containing mucin-like hormone receptor 2 in cancers
Among patients with EMR2-positive cancers, the clinicopathologic
significance of this protein varies by tumor type. In colorectal cancer,
EMR2 did not significantly affect clinical parameters such as tumor
stage or systemic invasion.35 However in breast cancer, EMR2 appears
to have a functional role in disease aggressiveness. EMR2 is highly
expressed in invasive carcinomas and a subset of ductal carcinoma in
situ (DCIS), but not in normal breast epithelium.36 When comparing in
situ and invasive carcinomas, EMR2 expression was significantly high-
er in the invasive group, suggesting that EMR2 may contribute to this
invasive phenotype.36 Interestingly, among these invasive carcinomas,
increased cytoplasmic expression of EMR2 was found to correlate with
a higher tumor grade, while increased nuclear expression of EMR2 cor-
related with prolonged relapse-free survival and overall survival.36 In
DCIS, EMR2 expression did not show any correlation with important
clinical and pathologic parameters such as patient age, tumor grade,
estrogen receptor positivity, tumor progression, or overall survival.36
Our group recently characterized the functional significance of
EMR2 and its fellow EGF-TM7 member EMR3 in human GBM.37,40 EMR2
was found to confer an invasive phenotype in vitro, with no effect on
tumor proliferation. More importantly, when stratifying tumors by their
relative expression of EMR2, there is an inverse relationship between
EMR2 gene expression and overall survival; patients whose tumors
express high levels of EMR2 were found to have significantly shorter
overall survival compared to those with tumors expressing low levels of
EMR2, suggesting that EMR2 expression may represent a clinically rel-
evant biomarker in this disease.37,40 We believe that the survival dis-
crepancy among patients with high versus low EMR2 expressing
tumors is likely related to the invasive potential of their tumors. The
mechanisms underlying EMR2 expression in GBM are not well under-
stood, nor are the possible downstream targets of the receptor, howev-
er the upregulation of EGF-TM7 family members in GBM may represent
a unique genetic subtype characterized by a highly invasive phenotype,
a step in tumor oncogenesis that provides a selective advantage due to
its invasive potential. 
Functional data suggest that EMR2 may serve as a biomarker of
increased malignancy or invasive potential in breast cancer and GBM,
although perhaps not in colorectal, gastric, pancreatic, and esophageal
cancers (Table 1). EMR2 is also a useful cell surface marker for tumor-
infiltrating macrophages and neutrophils. Taken together, EMR2 is a
critically important member of the EGF-TM7 family that may one day
help stratify patients by tumor phenotype, allow for more accurate prog-
noses, and serve as a target for novel therapeutic agents. CD97, which
shares significant homology with EMR2, has been the target of thera-
peutic intervention through neutralizing antibodies and a proposed
vaccine against its ligand CD55; perhaps a similar approach can be
used for EMR2.41,42 Such inhibition of EMR2 may represent one strate-
gy for limiting local and systemic invasion of neoplastic cells. Given
that EMR2 expression has been tied to patient survival, such therapies
could conceivably improve clinical outcomes for patients with EMR2-
positive tumors.  
Review
Conclusions
The association of the EGF-TM7 family member EMR2 with multiple
human cancers poses interesting questions with respect to how and
why neoplastic cells would upregulate their expression of leukocyte
receptors. Leaning on data demonstrating the role of these proteins in
adhesion, migration, invasion, and angiogenesis, it is reasonable to
postulate that EMR2-positive neoplasms possess a greater capacity for
infiltrative and metastatic spread. Accordingly, therapies targeting
EMR2 may be useful in attenuating both local and systemic invasion,
though it remains to be seen whether a clinically relevant response is
achievable. One may also hypothesize that EMR2 facilitates immune
evasion in cancer cells, as the presence of EGF-TM7 family members on
the surface of normal leukocytes may compromise the host’s ability to
mount an effective immune response against EMR2-expressing cancer
cells. Moving forward, recognized challenges in the study of adhesion-
GPCRs include their complex chimeric protein structure, limited
knowledge of downstream intracellular targets, and paucity of
reagents.43 Nonetheless, ongoing advances in structural and molecular
biology, genome-wide analyses such as the Cancer Genome Atlas, and
accumulating data on the role of the EGF-TM7 family in neoplastic
states will shed new insight into these markers and aid in the develop-
ment of targeted therapies for patients with aggressive and often high-
ly invasive cancers. 
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